A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection

Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.

Study Overview

• Status: Terminated
• Conditions: Hepatitis B
• Intervention / Treatment: Drug: entecavir; Drug: tenofovir; Other: placebo; Drug: antihistamine; Drug: ARC-520 Injection

Detailed Description

This is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 in combination with entecavir or tenofovir administered to patients with Hepatitis B 'e' Antigen (HBeAg) negative and immune active chronic HBV infection. Eligible patients who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 or placebo in combination with entecavir or tenofovir. The study will enroll up to a total of 60 eligible chronic HBV infected patients. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events assessment (AEs), 12-lead electrocardiograms (ECGs), liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation,chemistry, lactate, Pharmacokinetic (PK) measures (in a subset of patients), exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient, the duration of the study is approximately 33 weeks from screening to the Day 169 follow-up visit. For patients enrolling into a planned extension study, the total duration of this study is approximately 25 weeks from screening to Day 113 end of study visit.

• Study Type: Interventional
• Enrollment (Actual): 58
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Hong Kong, China
    • Prince of Wales Hospital
  • Hong Kong, China, 999077
    • Queen Mary Hospital
• Germany
  • Frankfurt, Germany, 60590
    • Klinikum der Johann Wolfgang Goethe Universitaet
  • Hamburg, Germany, 20099
    • Asklepios Klinik St. Georg - Chirurgisch-Traumatologisches Zentrum
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
  • Leipzig, Germany, 04103
    • Eugastro GmbH
  • Leipzig, Germany, 4103
    • Universitaetsklinikum Leipzig
  • Muenchen, Germany, 81377
    • Klinikum Der Ludwig-Maximilian-Universitaet Muenchen
  • Tuebingen, Germany, 72076
    • University Hospital Of Tuebingen
  • Ulm, Germany, 89081
    • Universitaetsklinikum Ulm, Klinik fur Innere Medizin I
  • Wuerzburg, Germany, 97080
    • Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II
• Korea, Republic of
  • Busan, Korea, Republic of, 602-739
    • Pusan National University Hospital
  • Incheon, Korea, Republic of, 405-760
    • Gachon University Gil Medical Center
  • Seoul, Korea, Republic of, 110-744
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 120-752
    • Severance Hospital, Yonsei University College of Medicine
  • Yangsan-si Gyeongnam, Korea, Republic of, 626-770
    • Pusan National University Yangsan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female, 18 to 75 years of age
• Written informed consent
• No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment
• No new abnormal finding of clinical relevance at the screening evaluation.
• Diagnosis of HBeAg negative, immune active, chronic HBV infection
• > 2 months of continuous treatment with daily, oral entecavir or tenofovir
• Willingness to continue taking entecavir or tenofovir throughout the study.
• Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners)

Exclusion Criteria:

• Pregnant or lactating
• Acute signs of hepatitis/other infection within 4 weeks of screening
• Antiviral therapy other than entecavir or tenofovir within 3 months of screening
• Prior treatment with interferon in the last 3 years.
• Use within the last 6 months or anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants.
• Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, or hormonal contraceptives.
• Depot injection or implant of any drug within 3 months prior to treatment administration, except injectable/implantable birth control.
• Diagnosis of diabetes mellitus.
• History of autoimmune disease especially autoimmune hepatitis.
• Human immunodeficiency virus (HIV) infection.
• Sero-positive for Hepatitis C Virus (HCV), and/or a history of delta virus hepatitis.
• Hypertension defined as blood pressure > 150/100 mmHg
• History of cardiac rhythm disturbances
• Family history or congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death
• Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease within 6 months prior to study entry.
• History of malignancy except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer.
• Has had a major surgery within 3 months of screening.
• History of alcohol and/or drug abuse < 12 months from screening.
• Regular uses of alcohol within 6 months prior to screening (ie, more than 14 units of alcohol per week).
• Evidence of severe systemic acute inflammation, sepsis, or hemolysis.
• Diagnosed with a significant psychiatric disorder.
• Use of recreational drugs, such as marijuana, within 3 months prior to screening
• Use of drugs such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year prior to screening.
• History of allergy to bee sting.
• Use of investigational agents or devices within 30 days prior to planned study dosing or current participation in an investigational study.
• Clinically significant history or presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease.
• Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction.
• Clinically significant history or presence of poorly controlled/uncontrolled systemic disease.
• History of fever within 2 weeks of screening.
• Immunized with a live attenuated vaccine within 7 days prior to dosing or planned vaccination (excluding flu vaccine by injection).
• Presence of any medical or psychiatric condition or social situation that impacts compliance or results in additional safety risk.
• Participated in excessive exercise/physical activity within 7 days of screening or planned during the trial.
• History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant medication(s).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: PBO Low Dose; 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period	Drug: entecavir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: tenofovir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Other: placebo; Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.; Drug: antihistamine; All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Placebo Comparator: PBO High Dose; 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period	Drug: entecavir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: tenofovir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Other: placebo; Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.; Drug: antihistamine; All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Experimental: ARC-520 Injection 1 mg/kg; Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period	Drug: entecavir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: tenofovir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: antihistamine; All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.; Drug: ARC-520 Injection; ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
Experimental: ARC-520 Injection 2 mg/kg; Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period	Drug: entecavir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: tenofovir; All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.; Drug: antihistamine; All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.; Drug: ARC-520 Injection; ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113	Change From Baseline in log qHBsAg at Day 113 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.	Baseline, Day 113

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Maximum Observed Plasma Concentration (Cmax)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Clearance (CL)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Apparent Volume of Distribution (V)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Terminal Elimination Rate Constant (Kel)		Through 48 hours post-dosing on Day 1 and Day 85
Pharmacokinetics of ARC-520: Terminal Elimination Half-Life (t1/2)		Through 48 hours post-dosing on Day 1 and Day 85
Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) Over Time	Change From Baseline in log qHBsAg at Day 113 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.	Baseline, Day 15, 29, 43, 57, 71, 85, 99
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs	An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. An SAE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction. A treatment emergent AE (TEAE) was defined as an AE that was not present prior to the first study medication administration and started at/after the time of initiation of administration of study medication, or an AE which was present prior to initiation of study medication administration, which increased in severity after study medication administration.	Through Day 169

Collaborators and Investigators

• Sponsor: Arrowhead Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2015
• Primary Completion (Actual): January 1, 2017
• Study Completion (Actual): January 1, 2017

Study Registration Dates

• First Submitted: November 11, 2015
• First Submitted That Met QC Criteria: November 11, 2015
• First Posted (Estimate): November 13, 2015

Study Record Updates

• Last Update Posted (Actual): April 16, 2019
• Last Update Submitted That Met QC Criteria: January 11, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Histamine Agents; Tenofovir; Entecavir; Histamine H1 Antagonists; Histamine Antagonists
• Other Study ID Numbers: Heparc-2002; 2014-004145-27 (EudraCT Number)